Type 1 Diabetes Research

A Step Into Freedom From T1DM

About Me

Hello

I amShivani Desai

Type 1 diabetes researcher and enthusiast

Welcome to T1DM.org! It is a platform which consolidates my work about type 1 diabetes (T1DM) and its management. This forum invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease.

This forum includes the papers published by the author in the journals of repute. These papers primarily involve the content related to the etiology and pathophysiology of T1DM, the application of mesenchymal stem cells to manage T1DM and improve the quality of life in patients, and the correlation of diabetes with hepatic dysfunctions. It also includes papers related to the immunological aspects in the journey to prevent and reverse the disease.

With more interaction and collaborations, we can bring an end to T1DM and give a better life to the children who are at risk to develop this immensely agonising disease.

2 Patents

Diabetec foot ulcer (DFU) treatment using stem cell, Wound healing

26 Publications

T1DM vaccine research, Regenerative medicine research, 15 under process

10 Awards

'Woman Innovator' National Award 2022 and others, for research in T1DM

Journey So Far

2016

July

Inception of Idea

Development of vaccine to prevent and reverse type 1 diabetes mellitus

2018

September

t1dm.org Launched

Platform launched to consolidate research work about type 1 diabetes and its management

t1dm.org invites an open interaction from national and international experts to manage type 1 diabetes, share their knowledge and collaborate to work towards freedom from this painful disease

2020

June

Research Publication

First review paper on type 1 diabetes mellitus “Mapping of type 1 diabetes mellitus” published in Current Diabetes Reviews

2021

December

Preclinical Model Development

Preclinical model development project using Swiss albino mice started to study type 1 diabetes

2022

April

Phase 1 Preclinical Study

Stability test for vaccine formula conducted
Allergy test and safety study for vaccine formula conducted
Efficacy study of vaccine formula to prevent and reverse type 1 diabetes mellitus

My Latest Publications

[Meta Analysis] Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes

Background and objective: Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.
Authors: Prajakta Kashalikar, Shivani Desai, Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde

Journal: Recent Advances in Inflammation & Allergy Drug Discovery (Formerly as Recent Patents on Inflammation & Allergy Drug Discovery)

Keywords: Immunotherapy; Meta-analysis; Rituximab; Teplizumab; Type1Diabetes

Read Full Review Paper

[Review Paper] Nanotechnology: Newer Approach in Insulin Therapy

Abstract: Insulin is a peptide hormone released by pancreatic beta cells. An autoimmune reaction in diabetes mellitus type 1 causes the beta cells to die, preventing insulin from being produced or released into the bloodstream which impacts 30 million people globally and is linked to shortened lifespan due to acute and chronic repercussions. Insulin therapy aims to replicate normal pancreatic insulin secretion, which includes low levels of insulin that are always present to support basic metabolism, as well as the two-phase secretion of additional insulin in response to high blood sugar - an initial spike in secreted insulin, followed by an extended period of continued insulin secretion. This is performed by combining various insulin formulations that work at varying rates and for different lengths of time. Since the beginning of human insulin use, several advances in insulin formulations have been made to help meet these aims as much as possible, resulting in improved glycaemic control while limiting hypoglycaemia. In this review, we looked at devices used by patients with type 1 diabetes, such as insulin pumps, continuous glucose monitors, and, more recently, systems that combine a pump with a monitor for algorithm-driven insulin administration automation. We intend to provide insight into supplementary therapies and nanotechnology employed in insulin therapy as a result of our review. 


Journal: Pharmaceutical Nanotechnology 

Keywords: Basal Bolus Insulin; Continuous Glucose Monitoring (CGM); Insulin Pump Therapy; Insulin glargine U300; Nanotechnology 

[Review Paper] Nanobiotechnology-Modified Cellular and Molecular Therapy as a Novel Approach for Autoimmune Diabetes Management

Abstract: Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management.


Journal: Pharmaceutical Nanotechnology

Keywords: Autoimmunity; Immunotherapy; Nanocarriers; Stem cell; Tolerance; Type 1 diabetes

Read Full Review Paper

[Review Paper] Managing Type 1 Diabetes from Gynecological Waste: Trash to Treasure

Abstract: Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves the destruction of pancreatic β cells. β cells maintain glucose homeostasis by identifying blood glucose and accordingly releasing insulin in order to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells posture a lesser risk of viral contamination as there is low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynaecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access as compared to deriving stem cells from other sources. According to the published preclinical data infusion of autologous cord blood cells is considered to be safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves, and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) embraces the great potential for the management of T1DM due to their regenerative capabilities and their promising immunological characteristics. Due to lesser ethical complications and easy procedures of isolation, hUCB has become a precious medical intervention.

Journal: Current Diabetes Review

Keywords: Umbilical cord blood stem cells; glucose homeostasis; gynecological waste; immunogenicity; plasticity; type 1 diabetes mellitus.

Read Full Review Paper


[Review Paper] Managing Type 1 Diabetes from Gynecological Waste: Trash to Treasure


Abstract
: Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves destruction of pancreatic β cells. β cells maintains glucose homeostasis by identifying blood glucose and accordingly releasing insulin in order to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells posture a lesser risk of viral contamination as there is low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access as compared to deriving stem cells from other sources. According to the published preclinical data infusion of autologous cord blood cells is considered to be safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves, and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) embraces great potential for the management of T1DM due to their regenerative capabilities and their promising immunological characteristics. Due to lesser ethical complications and easy procedures of isolation, hUCB has become a precious medical intervention.

Journal: Current Diabetes Review

Keywords: Umbilical cord blood stem cells; glucose homeostasis; gynecological waste; immunogenicity; plasticity; type 1 diabetes mellitus.

Read Full Review Paper

[Video] Pathophysiology and Pharmacology of Type 1 Diabetes Mellitus

I recently delivered a lecture at Masters Certificate Course in Diabetic Pharmacotherapy (MCCDP), hosted by CliMed Research Solutions on the topic of 'Pathophysiology and Pharmacology of Type 1 Diabetes Mellitus'. Special thanks to Dr Ajit Singh for this opportunity! 

Understanding the disease's pathophysiology can help in managing it better. The following video is a deep dive into this approach. 

For more videos and discussions on T1DM, visit: https://www.t1dm.org

For queries or feedback, email info@t1dm.org or simply leave a comment below.

[Editorial] Th1-Th2 Seesaw: An Essential Aspect in Type 1 Diabetes


Balanced Th1 and Th2 cytokines are significantly associated to maintain the immunological ecosystem in human physiology. Any imbalance can lead to either autoimmune diseases or immunodeficient diseases. This editorial highlights the immunological mechanism involved in type 1 diabetes (T1DM).

Journal: Current Diabetes Reviews

Keywords: Cytokines; T1D; T2D; anti-inflammatory; immunological processes; proinflammatory

Read Full Editorial

Testimonials

Collaborate With Me

Contact Us

SHIVANI DESAI
+91-20-4930-0148
Pune, India